Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03156504 · ClinicalTrials.gov registry record · Phase 4
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
A Phase 4 study of Major Depression and Bipolar I Disorder, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 4
- Study locations
NCT03156504 is a Phase 4 study of Major Depression and Bipolar I Disorder that has completed, run by Mayo Clinic. The registered enrollment target is 75 participants, below the 325-participant average among 28 other Major Depression trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03156504, a Phase 4 study of Major Depression and Bipolar I Disorder, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to find out if the medication known as ketamine can help the symptoms of depression. This drug is approved by the Food and Drug Administration (FDA) but the investigators will use it for a non-FDA approved reason (depression).
Conditions Studied
Interventions
- DRUG Ketamine Hydrochloride
Study Locations (4)
Maryland
- Johns Hopkins Hospital - Baltimore
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2020-03-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03156504
The ClinicalTrials.gov registry entry for NCT03156504 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 325-participant average among 28 other Major Depression trials with a reported enrollment target (77% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Major Depression appearing as the primary indexed condition, and to 1 intervention - of which Ketamine Hydrochloride is the first listed.
NCT03156504 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Maryland, Michigan, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03156504 about?
NCT03156504 is a clinical study titled "The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.". The purpose of this research study is to find out if the medication known as ketamine can help the symptoms of depression. This drug is approved by the Food and Drug Administration (FDA) but the investigators will use it for a non-FDA approved reason (depression).
What is the current status of trial NCT03156504?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2017-06-01. Estimated completion is 2020-03-12.
What conditions does trial NCT03156504 study?
This clinical trial studies the following conditions: Major Depression, Bipolar I Disorder, Bipolar II Disorder, Unipolar Depression.
What interventions are being tested in trial NCT03156504?
The interventions under investigation include: Ketamine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03156504?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03156504 being conducted?
This trial has 4 study locations across Maryland, Michigan, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.
COMPLETED · Phase 4
-
Preventing Depression Recurrence in Diabetes
COMPLETED · Phase 4
-
Pharmacotherapy in Depression With Panic Spectrum
COMPLETED · Phase 4
-
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
COMPLETED · Phase 4
-
Prozac Treatment of Major Depression: Discontinuation Study
COMPLETED · Phase 4
-
Thyroid Medication and Antidepressants for Treating Major Depression
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.